TSX:MBX - CA59501P1045 - Common Stock
The current stock price of MBX.CA is 0.235 CAD. In the past month the price decreased by -20.34%. In the past year, price decreased by -38.16%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
EDT.CA | SPECTRAL MEDICAL INC | N/A | 425.87M | ||
FRX.CA | FENNEC PHARMACEUTICALS INC | N/A | 343.98M | ||
EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 266.82M | ||
TH.CA | THERATECHNOLOGIES INC | N/A | 204.61M | ||
BCT.CA | BRIACELL THERAPEUTICS CORP | N/A | 201.40M | ||
ONC.CA | ONCOLYTICS BIOTECH INC | N/A | 126.12M | ||
HBP.CA | HELIX BIOPHARMA CORP | N/A | 100.86M | ||
WLLW.CA | WILLOW BIOSCIENCES INC | N/A | 97.56M | ||
MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 90.92M | ||
BLU.CA | BLUENERGIES LTD | N/A | 82.42M | ||
COV.CA | COVALON TECHNOLOGIES LTD | 18.46 | 65.81M | ||
MSCL.CA | SATELLOS BIOSCIENCE INC | N/A | 60.21M |
Microbix Biosystems, Inc. engages in developing and commercializing proprietary biological and technology solutions for human health and wellbeing. The company is headquartered in Mississauga, Ontario. The company enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.
MICROBIX BIOSYSTEMS INC
265 Watline Avenue
Mississauga ONTARIO L4Z 1P3 CA
CEO: Cameron Groome
Employees: 0
Phone: 19053618910
The current stock price of MBX.CA is 0.235 CAD. The price decreased by -2.08% in the last trading session.
The exchange symbol of MICROBIX BIOSYSTEMS INC is MBX and it is listed on the Toronto Stock Exchange exchange.
MBX.CA stock is listed on the Toronto Stock Exchange exchange.
5 analysts have analysed MBX.CA and the average price target is 0.92 CAD. This implies a price increase of 290.64% is expected in the next year compared to the current price of 0.235. Check the MICROBIX BIOSYSTEMS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
MICROBIX BIOSYSTEMS INC (MBX.CA) has a market capitalization of 32.91M CAD. This makes MBX.CA a Nano Cap stock.
MICROBIX BIOSYSTEMS INC (MBX.CA) currently has 0 employees.
MICROBIX BIOSYSTEMS INC (MBX.CA) has a resistance level at 0.24. Check the full technical report for a detailed analysis of MBX.CA support and resistance levels.
The Revenue of MICROBIX BIOSYSTEMS INC (MBX.CA) is expected to grow by 7.14% in the next year. Check the estimates tab for more information on the MBX.CA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
MBX.CA does not pay a dividend.
MICROBIX BIOSYSTEMS INC (MBX.CA) will report earnings on 2025-12-17.
ChartMill assigns a fundamental rating of 6 / 10 to MBX.CA. While MBX.CA has a great profitability rating, there are some minor concerns on its financial health.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -0.85% | ||
ROE | -1.11% | ||
Debt/Equity | 0.21 |
5 analysts have analysed MBX.CA and the average price target is 0.92 CAD. This implies a price increase of 290.64% is expected in the next year compared to the current price of 0.235.
For the next year, analysts expect an EPS growth of 50% and a revenue growth 7.14% for MBX.CA